RxElite Holdings, Inc., a wholly owned subsidiary of Southridge Technologies Group Inc., develops, manufactures, and markets generic prescription drug products in specialty generic markets. Key markets include anesthesia, sterile liquid dose drugs, and transdermal patch products. RxElite Holdings, Inc. recently closed a $19.6 Million Financing.

Recent Drug Approval/ High Barriers With Limited Competition:
Sevoflurane, the Company’s primary product was approved in May 2007. RxElite has the exclusive US rights to this product, a $400 M market with only two competitors. High barriers to additional competition include manufacturing process patents, limited manufacturing capacity, and unique chemistry expertise requirements.

Distribution Strength and Key Customers:
RxElite has established distribution agreements to over 90% of the US market for generic drugs. Key select customers include Wal-Mart, Walgreens, McKesson, and Cardinal Health.

Aggressive and Full Pipeline:
RxElite has over 10 products in its pipeline. The Company plans to launch new products in each of the next 12 months over the next three years, targeting over $2 Billion in new addressable markets.